29.08.22|James SpiroIn a climate where companies are cutting costs, one thing is worth holding on to: your patents.
03.03.22|Guillaume SternIn a few months, the United Patent Court and the European Patent System will start operating differently, having significant implications for those seeking to protect their Intellectual Property
08.11.21|Saleit Shahar"Early-stage startups have limited financial and human resources to invest in IP. Together with the inherent problems in evaluating IP assets, startups do not always prioritize IP protection. However, as sometimes realized, the costs of lacking IP are higher," writes Saleit Shahar
31.12.20|CTechSilicon Valley investor Steve Krawczyk talks to Michael Matias about the importance of grabbing opportunities, how patents play out in the pharma industry, and his role as an “emotional support angel”
25.11.20|Adv. Ephraim HeiliczerWhile regulatory exclusivity will effectively protect Covid vaccines for at least a decade in Europe and the U.S, they will be unprotected by regulatory exclusivity in Israel.
15.11.20|CTechContest is open to startups at seed and series A stages, top three winners will be awarded strategic, digital marketing, and storytelling services worth up to NIS 100,000
29.10.20|Adv. Nathan RenovMasks, decorations, and social distancing - here are the patents that are keeping us safe in a Halloween spooked with Covid-19
23.10.20|Allon SinaiDaniel Kligler, who specializes in patents, offers his unique insights on what makes Israelis dominate tech innovation
15.06.20|Hagar RavetShould the new model be adopted it would offer innovators a more accessible and less pricey route to patenting and could prove a source of revenue for the Israeli economy, according to intellectual property lawyer and former patent office director Asa Kling
08.06.20|Chavah Apfelbaum and Syvanne AloniPioneers, who are navigating fragmented intellectual property laws across global markets, must be astute if they are to benefit from the significant commercial and geopolitical value of Covid-19-related ideas and products
24.03.19|CTechUnder the settlement agreement, Teva will be able to sell a generic version of the drug as of 2023
03.01.19|Lilach BaumerIn December, Teva reached a confidential settlement and licensing agreement with drug manufacturer Neos Therapeutics, regarding its generic version for Neos' ADHD drug
27.12.18|CTechThe agreement will enable Teva to manufacture and sell a generic version of Neos’ ADHD drug Cotempla as of 2026
05.12.18|Lilach BaumerTeva was sued in 2011 by Swiss drug company Helsinn Healthcare over its intention to develop a generic version of Helsin's drug, which it released in the U.S. in March 2018
27.08.18|Meir OrbachAccording to a new report by Israel's Central Bureau of Statistics, the number of newly registered patents in 2017 was down 5% compared with the year before. Registered scientific discoveries were down 19%
28.05.18|Zohar Shahar LevyIsraeli immunologist Zelig Eshhar, who holds the patent for Kite Pharma’s anti-cancer technology, has been sued by a former student for infringement of patent rights
16.01.18|Zohar Shahar LevyZelig Eshhar, the patent holder for Kite Pharma’s anti-cancer technology, is currently being sued by a former student for infringement of patent rights
26.12.17|Zohar Shahar LevyIn August, Gilead Science bought anti-cancer treatment company Kite Pharma for $11.9 billion. Two Israeli scientists involved in the early research that led to the company’s breakthrough are now quarreling over patent royalty payments
26.10.17|Lilach BaumerMylan and European Partner Synthon won U.K. patent case related to Teva's Copaxone
22.10.17|Zachi ZachIf not carefully selected, a startup contest could hold more risk than value